Previous 10 | Next 10 |
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the Company has regained the commercialization and dis...
Conference Call to be Held on Thursday, May 14, 2020 at 5:00 p.m. (EDT) Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, tod...
Despite headwinds from the COVID-19 pandemic affecting all companies, Navidea Biopharmaceuticals ( NAVB +4.4% ) says its efforts on advancing its pipeline remain on track. Key points: More news on: Navidea Biopharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read mor...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces the following statement regarding the impact of the COVID-19 pandemic on...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has signed a letter of intent (“LOI”) to par...
Navidea Biopharmaceuticals (NYSEMKT: NAVB ) is up 26% premarket after the USPTO issued a Certificate to extend the duration of U.S. patent 6,409,990 for an additional five years through May 12, 2025. More news on: Navidea Biopharmaceuticals, Inc., Healthcare stocks news, Stoc...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on March 17, 2020 the U.S. Patent and Trademark Office ( ...
Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2019 Results Earnings Conference Call March 11, 2020, 5:00 pm ET Company Participants Jed Latkin - Chief Executive Officer, Chief Financial Officer, Chief Operating Officer Mike Rosol - Chief Medical Officer Erika Eves - Director Finance...
Navidea Biopharm (NYSEMKT: NAVB ): Q4 GAAP EPS of -$0.15 misses by $0.01 . Revenue of $0.12M (flat Y/Y) misses by $0.03M . Press Release More news on: Navidea Biopharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
Conference Call to be held Wednesday, March 11, 2020 at 5:00 pm EDT Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today a...
News, Short Squeeze, Breakout and More Instantly...
Navidea Biopharmaceuticals Inc. Company Name:
NAVB Stock Symbol:
NYSE Market:
Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the &...
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focuse...
The Company announced today that the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the NYSE American LLC upheld the NYSE Regulation staff’s previously announced determination to initiate delisting proceedings with respect to the Company’s com...